Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Nov 08, 2022
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders Nov 08, 2022
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022 Nov 03, 2022
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia Oct 27, 2022
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Oct 06, 2022
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Oct 05, 2022
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences Oct 04, 2022
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer Oct 03, 2022
